Cardiac effects of growth hormone in short normal children: results after four years of treatment

P E F Daubeney, E S McCaughey, C Chase, J M Walker, Z Slavik, P R Betts, S A Webber

Abstract
Growth hormone excess is known to have adverse effects on the heart. The long term cardiac effects of growth hormone given to short normal children as part of a prospective randomised controlled trial of growth hormone treatment (Genotropin 30 IU/m2/week or no treatment) were therefore investigated. Echocardiographic findings are presented for 28 children who have been followed up for a minimum of four years.

At the outset, the treated (n=15) and untreated groups (n=13) did not differ for any anthropometric or echocardiographic parameter. Their mean (SD) age at onset was 7.8 (0.5) years. After four years of treatment mean height SD score increased from -2.4 to -1.2 compared with no change (-2.8) in the untreated group. Left ventricular posterior wall and septal thickness and left ventricular shortening fraction did not differ between the groups, but a tendency towards increased left ventricular mass was seen in the treatment group (93±73 g). No such differential was observed after indexing left ventricular mass for body surface area (79±71 g/m²) or lean body mass (3-15±3-05 g/kg).

It is concluded that prolonged growth hormone treatment does not cause important changes to the heart. A tendency towards increased left ventricular mass simply reflects the increase in lean body mass during treatment.

(Keywords: growth hormone, short stature, cardiac function.)

PATIENT CHARACTERISTICS
Mean (SD) age at onset of the trial was 7.8 (0.9) years. There was a similar sex distribution in the two groups with seven boys and eight girls in the treated group and seven boys and six girls in the untreated group. As previously described, there were no differences between the groups at the onset of the study for age, sex, height, parental height, birth weight, bone age, or socioeconomic status. All children were white. All were initially prepubertal. By year 4 none of the boys in the untreated group had reached puberty. Three of the boys in the treated group were Tanner stage 2. In both groups all girls were in stage 2 or 3 except for one girl in each group who had reached stage 4.

ANTHROPOMETRIC DATA
Height, weight, and skinfold thickness (from biceps, triceps, subscapular, and suprailiac sites) were measured every six months as previously described. Body fat was calculated using the method of Brook and Siri.7 8 and hence lean body mass derived (total weight−weight of body fat). Body surface area (BSA) was calculated from the following formula: BSA=weight0.425×height0.727184.8 Blood pressure was measured at the year 3 examination.
Table 1  Comparison of treated and untreated groups at year 0 (that is, before start of growth hormone treatment). Data expressed as mean (SD) for treated and untreated groups; difference between means shown with SE; p value shown for unpaired two tailed t test between groups

<table>
<thead>
<tr>
<th>Anthropometric data</th>
<th>Treated</th>
<th>Untreated</th>
<th>Difference between means</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Height (cm)</td>
<td>111 (3)</td>
<td>110 (3)</td>
<td>1 (0.9)</td>
<td>NS</td>
</tr>
<tr>
<td>Height SD score</td>
<td>-2.4 (0.3)</td>
<td>-2.5 (0.4)</td>
<td>0.1 (0.1)</td>
<td>NS</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>18.6 (2.2)</td>
<td>18.7 (1.8)</td>
<td>-0.1 (0.8)</td>
<td>NS</td>
</tr>
<tr>
<td>BSA (m²)</td>
<td>0.75 (0.05)</td>
<td>0.75 (0.04)</td>
<td>0.0 (0.0)</td>
<td>NS</td>
</tr>
<tr>
<td>LBM (kg)</td>
<td>16.2 (1.6)</td>
<td>16.3 (1.3)</td>
<td>-0.1 (0.6)</td>
<td>NS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Echocardiographic measurements</th>
<th>Treated</th>
<th>Untreated</th>
<th>Difference between means</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posterior wall (mm)</td>
<td>6.1 (1.8)</td>
<td>5.8 (1.2)</td>
<td>0.3 (0.6)</td>
<td>NS</td>
</tr>
<tr>
<td>Septum (mm)</td>
<td>5.6 (1.3)</td>
<td>6.2 (1.3)</td>
<td>-0.6 (0.6)</td>
<td>NS</td>
</tr>
<tr>
<td>LVIDd (mm)</td>
<td>22.7 (3.2)</td>
<td>21.2 (3.3)</td>
<td>1.5 (1.7)</td>
<td>NS</td>
</tr>
<tr>
<td>LVIDd (mm)</td>
<td>35.8 (4.0)</td>
<td>33.9 (5.1)</td>
<td>1.9 (1.9)</td>
<td>NS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Echocardiographic derivations</th>
<th>Treated</th>
<th>Untreated</th>
<th>Difference between means</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fractional shortening (%)</td>
<td>37.0 (4.2)</td>
<td>38.1 (8.7)</td>
<td>-1.1 (2.6)</td>
<td>NS</td>
</tr>
<tr>
<td>LVM (g)</td>
<td>52.8 (17.1)</td>
<td>49.1 (12.7)</td>
<td>3.7 (6.6)</td>
<td>NS</td>
</tr>
<tr>
<td>LVM index (g/m²)</td>
<td>69.9 (22.2)</td>
<td>66.7 (18.6)</td>
<td>3.2 (9.9)</td>
<td>NS</td>
</tr>
<tr>
<td>LVM/LBM (g/kg)</td>
<td>3.25 (1.0)</td>
<td>3.08 (0.86)</td>
<td>0.17 (0.40)</td>
<td>NS</td>
</tr>
</tbody>
</table>

For abbreviations see text.

ECHOCARDIOGRAPHY

Echocardiograms were performed annually from year 0 to 4 using an HP Sonos 1000 or 1500 ultrasound machine (Hewlett Packard). All studies were performed by an experienced echocardiography technician; 3-5 or 5 MHz transducers were used as appropriate. M mode echocardiograms were performed using cross sectional image guidance. All M mode studies were performed using the standard techniques as described by the American Society of Echocardiography. The following measurements were obtained: thickness of the interventricular septum (IVST) and posterior wall (PWT), both at end diastole, left ventricular end diastolic internal diameter (LVIDd) and left ventricular end systolic diameter (LVIDs). From these parameters the following were derived:

FS of left ventricle (FS%) = 100(LVIDd - LVIDs)/LVIDd
LVM (g) = 1.04[(LVIDd + PWT + IVST) - LVIDd] - 13.6
LVM indexed for BSA (g/m²) = LVM/BSA
LVM indexed for LBM (g/kg) = LVM/LBM

FS = fractional shortening, LVM = left ventricular mass, LBM = lean body mass.

STATISTICAL ANALYSIS

Data are expressed as mean (SD). Height data are also expressed as SD scores. Treated and untreated groups were compared (at years 0 and 4) using the two tailed, two sample t test; p values <0.05 were considered significant.

Results

At the beginning of the study there were no significant differences between the two groups for any demographic, anthropometric, or echocardiographic variable or derivative (table 1).

ANTHROPOMETRIC DATA (TABLE 2)

There was an excellent response to growth hormone with the treated group consistently taller than the untreated group at each year of the study. The difference at year 4 being 141 (5) v 131 (5) cm (p<0.0005). Height SD score increased from -2.4 (0.3) to -1.2 (0.5) in the treated group, compared with no change in the untreated group (2.5 (0.4) at 0 and 4 years). Weight, body surface area, and lean body mass were also greater in the treated group at year 4 (p=0.01, 0.001, and 0.0004 respectively).

BLOOD PRESSURE

There was no difference between the systolic blood pressures of the treated and untreated groups at year 3 (97 (8) v 92 (8) mm Hg). The diastolic pressure, however, was slightly increased (64 (7) v 57 (6) mm Hg; p=0.016).

ECHOCARDIOGRAPHY: DIMENSIONS (TABLE 2)

There was no significant difference in the thickness of the posterior wall and septum at year 4 between treated and untreated groups. Left ventricular internal dimensions were significantly larger in the treated group both in systole (27.5 (3.0) v 22.9 (4.6) mm; p=0.006) and diastole (40.6 (4.5) v 35.7 (4.9) mm; p=0.012).

ECHOCARDIOGRAPHY: DERIVATIONS (TABLE 2)

There was no statistically significant difference in the left ventricular shortening fraction between the groups. Left ventricular mass was larger in the treatment group during each year of the study. By year 4 the difference was 20 g, though this did not reach statistical significance (93 (33) v 73 (26) g; p=0.09). When left ventricular mass was indexed for body surface area and lean body mass, this differential was reduced (79 (25) v 71 (21) g/m²; p=0.36 and 3.15 (0.89) v 3.05 (0.87) g/kg; p=0.75 respectively).

Discussion

Synthetic growth hormone treatment is an accepted form of treatment for growth hormone deficiency. In recent years increasing numbers of short normal children have been started on long term courses of growth hormone, even though the efficacy and adverse effects of this treatment are not fully
Cardiac effects of growth hormone in short normal children: results after four years of treatment

established. Of particular concern is the possibility of adverse cardiovascular effects when growth hormone is given over a prolonged period. Conditions with excessive growth hormone secretion are known to be associated with an increase in cardiovascular morbidity and mortality. Acromegalic patients frequently have increased left ventricular mass, which may occur independently of systemic hypertension. These observations suggest that growth hormone has a direct anabolic effect on the heart and some authors have referred to a ‘specific acromegalic cardiomyopathy’.

It remains to be determined whether growth hormone given as replacement treatment or as treatment to short normal children has adverse cardiovascular effects. Growth hormone given as replacement treatment to growth hormone deficient adults has produced conflicting results. Cuno and colleagues reported an increase in left ventricular mass during replacement treatment without a change in mean arterial pressure. By contrast, Jorgensen and colleagues noted no difference in left ventricular mass in growth hormone deficient adults randomised to growth hormone replacement or placebo. Both these studies involved treatment for six months or less. Short normal children are frequently given growth hormone in a dosage approximately twice that for replacement treatment (for example 30 v 15 IU/m²/week), often for several years. It is clearly imperative to establish that there are no long term cardiovascular (or other) adverse effects of this controversial treatment. Only one prior study has addressed this issue. Barton and colleagues measured left ventricular dimensions and wall thickness in a group of short normal children receiving two different doses of growth hormone (20 or 40 IU/m²/week) or no treatment. After one year the control patients were randomised to one of the treatment groups. Echocardiographic findings were reported after one year of treatment. Increment in left ventricular mass was greater in the high dose treatment group, but was considered to be fully explained by the greater increase in body size (though the method of indexing for change in body size was not stated). It was concluded that no adverse effects on the heart are present after one year of growth hormone treatment, but whilst these preliminary results are reassuring, much longer follow up studies of these patients are required.

We have performed a unique, long term randomised study of growth hormone treatment in short normal children. The children have now completed four years of follow up and the study is ongoing. A particular strength of this study has been the maintained follow up of the control subjects. We have therefore had the opportunity to study the cardiovascular effects of long term growth hormone and contrast these to a well matched control group. At the onset of the study echocardiographic findings were almost identical between the two groups. After four years of treatment a trend towards increased left ventricular mass was present in the treated group. However, growth in this group was also clearly superior. After indexing for body surface area, these differences diminish. We previously noted a marked lipolytic effect of growth hormone treatment. Indexing left ventricular mass for lean body mass, to control for variations in total body fat, abolished any difference in left ventricular mass between the two groups.

These findings strongly suggest that four years of high dose growth hormone treatment does not have adverse effects on left ventricular wall thickness or mass. Systolic function as assessed by left ventricular shortening fraction also remains unaltered. Abnormalities of diastolic function have not been addressed by this study and warrant investigation. Although these results are reassuring, the role of growth hormone in this group of children still remains controversial.

PD is supported by the Wessex Cardiac Trust.